NCT03133234View on ClinicalTrials.gov

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

CompletedOBSERVATIONAL

Enrollment

47

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

September 13, 2017

Study Completion Date

September 13, 2017

Conditions

T790M Positive NSCLC Patients

Interventions

DRUG

osimertinib

Oral dose of 80mg once daily

Trial Locations (1)

Unknown

Kiang Wu Hospital, Macau

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY